Literature DB >> 12512512

HIV-1 subtype C reverse transcriptase and protease genotypes in Zimbabwean patients failing antiretroviral therapy.

Rami Kantor1, Lynn S Zijenah, Robert W Shafer, Solomon Mutetwa, Elizabeth Johnston, Robert Lloyd, Andrea von Lieven, Dennis Israelski, David A Katzenstein.   

Abstract

HIV-1 drug resistance mutations have been identified and characterized mostly in subtype B HIV-1 infection. The extent to which antiretroviral drugs select for drug resistance mutations in non-subtype B HIV-1 is not known. We obtained HIV-1 reverse transcriptase (RT) and protease sequences from 21 Zimbabwean patients failing antiretroviral drug therapy. We compared these sequences with 56 published RT and protease subtype C sequences from untreated patients, 990 RT and 1140 protease subtype B sequences from treated patients, and 340 RT and 907 protease subtype B sequences from untreated patients and identified four mutation categories of subtype C HIV-1. Seventeen of the 21 patients (81%) had known drug resistance mutations. Mutations at 15 RT and 11 protease positions were more common in subtype C isolates than in subtype B isolates. HIV-1 subtype C-infected individuals receiving antiretroviral therapy develop many of the known subtype B drug resistance mutations. Comparison of subtype C RT and protease sequences with a large database of subtype B sequences identified subtype C-specific polymorphisms and candidate drug resistance mutations.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12512512      PMCID: PMC2573400          DOI: 10.1089/088922202320935483

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  13 in total

1.  Recombinant strains of HIV type 1 in the United Kingdom.

Authors:  K L Barlow; I D Tatt; P A Cane; D Pillay; J P Clewley
Journal:  AIDS Res Hum Retroviruses       Date:  2001-03-20       Impact factor: 2.205

Review 2.  International perspectives on antiretroviral resistance. Nucleoside reverse transcriptase inhibitor resistance.

Authors:  C Loveday
Journal:  J Acquir Immune Defic Syndr       Date:  2001-03-01       Impact factor: 3.731

3.  Genotypic variation of HIV-1 reverse transcriptase and protease: comparative analysis of clade C and clade B.

Authors:  Z Grossman; N Vardinon; D Chemtob; M L Alkan; Z Bentwich; M Burke; G Gottesman; V Istomin; I Levi; S Maayan; E Shahar; J M Schapiro
Journal:  AIDS       Date:  2001-08-17       Impact factor: 4.177

4.  Naturally occurring decreased susceptibility of HIV-1 subtype G to protease inhibitors.

Authors:  D Descamps; C Apetrei; G Collin; F Damond; F Simon; F Brun-Vézinet
Journal:  AIDS       Date:  1998-06-18       Impact factor: 4.177

5.  Construction of evolutionary distance trees with TREECON for Windows: accounting for variation in nucleotide substitution rate among sites.

Authors:  Y Van de Peer; R De Wachter
Journal:  Comput Appl Biosci       Date:  1997-06

6.  Use of drug resistance sequence data for the systematic detection of non-B human immunodeficiency virus type 1 (HIV-1) subtypes: how to create a sentinel site for monitoring the genetic diversity of HIV-1 at a country scale.

Authors:  N Yahi; J Fantini; C Tourres; N Tivoli; N Koch; C Tamalet
Journal:  J Infect Dis       Date:  2001-03-27       Impact factor: 5.226

7.  Human immunodeficiency virus type 1 reverse-transcriptase and protease subtypes: classification, amino acid mutation patterns, and prevalence in a northern California clinic-based population.

Authors:  M J Gonzales; R N Machekano; R W Shafer
Journal:  J Infect Dis       Date:  2001-09-10       Impact factor: 5.226

8.  Impact of baseline polymorphisms in RT and protease on outcome of highly active antiretroviral therapy in HIV-1-infected African patients.

Authors:  A J Frater; A Beardall; K Ariyoshi; D Churchill; S Galpin; J R Clarke; J N Weber; M O McClure
Journal:  AIDS       Date:  2001-08-17       Impact factor: 4.177

9.  Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000.

Authors:  Saladin Osmanov; Claire Pattou; Neff Walker; Bernhard Schwardländer; Jose Esparza
Journal:  J Acquir Immune Defic Syndr       Date:  2002-02-01       Impact factor: 3.731

10.  Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations.

Authors:  R W Shafer; M J Kozal; M A Winters; A K Iversen; D A Katzenstein; M V Ragni; W A Meyer; P Gupta; S Rasheed; R Coombs
Journal:  J Infect Dis       Date:  1994-04       Impact factor: 5.226

View more
  15 in total

1.  Suboptimal adherence associated with virological failure and resistance mutations to first-line highly active antiretroviral therapy (HAART) in Bangalore, India.

Authors:  Maria L Ekstrand; Anita Shet; Sara Chandy; Girija Singh; Ranjani Shamsundar; Vidya Madhavan; Shanmugam Saravanan; Elsa Heylen; Nagalingeswaran Kumarasamy
Journal:  Int Health       Date:  2011-03       Impact factor: 2.473

2.  Comparing Peripheral Blood Mononuclear Cell DNA and Circulating Plasma viral RNA pol Genotypes of Subtype C HIV-1.

Authors:  Lauren Banks; Sharareh Gholamin; Elizabeth White; Lynn Zijenah; David A Katzenstein
Journal:  J AIDS Clin Res       Date:  2012-02

3.  Prevalence and pattern of drug resistance mutations among antiretroviral-treated HIV-1 patients with suboptimal virological response in Malaysia.

Authors:  Kok Keng Tee; Adeeba Kamarulzaman; Kee Peng Ng
Journal:  Med Microbiol Immunol       Date:  2006-01-11       Impact factor: 3.402

4.  Envelope coreceptor tropism, drug resistance, and viral evolution among subtype C HIV-1-infected individuals receiving nonsuppressive antiretroviral therapy.

Authors:  Seble Kassaye; Elizabeth Johnston; Bryan McColgan; Rami Kantor; Lynn Zijenah; David Katzenstein
Journal:  J Acquir Immune Defic Syndr       Date:  2009-01-01       Impact factor: 3.731

5.  Characterization of a subtype D human immunodeficiency virus type 1 isolate that was obtained from an untreated individual and that is highly resistant to nonnucleoside reverse transcriptase inhibitors.

Authors:  Yong Gao; Ellen Paxinos; Justin Galovich; Ryan Troyer; Heather Baird; Measho Abreha; Cissy Kityo; Peter Mugyenyi; Christos Petropoulos; Eric J Arts
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

6.  Nucleotide and amino acid polymorphisms at drug resistance sites in non-B-subtype variants of human immunodeficiency virus type 1.

Authors:  Dan Turner; Bluma Brenner; Daniela Moisi; Mervi Detorio; Raymond Cesaire; Takashi Kurimura; Haruyo Mori; Max Essex; Shlomo Maayan; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

7.  HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme.

Authors:  Catherine Orrell; Rochelle P Walensky; Elena Losina; Jennifer Pitt; Kenneth A Freedberg; Robin Wood
Journal:  Antivir Ther       Date:  2009

8.  Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa.

Authors:  Vincent C Marconi; Henry Sunpath; Zhigang Lu; Michelle Gordon; Kofi Koranteng-Apeagyei; Jane Hampton; Steve Carpenter; Janet Giddy; Douglas Ross; Helga Holst; Elena Losina; Bruce D Walker; Daniel R Kuritzkes
Journal:  Clin Infect Dis       Date:  2008-05-15       Impact factor: 9.079

9.  One-, two-, and three-class resistance among HIV-infected patients on antiretroviral therapy in private care clinics: Mumbai, India.

Authors:  Amita Gupta; Dattaray G Saple; Girish Nadkarni; Bijal Shah; Satish Vaidya; Nitin Hingankar; Devidas Chaturbhuj; Praveen Deshmukh; Louise Walshe; Sarah E Hudelson; Maria James; Ramesh S Paranjape; Susan H Eshleman; Srikanth Tripathy
Journal:  AIDS Res Hum Retroviruses       Date:  2010-01       Impact factor: 2.205

10.  Genotypic HIV type-1 drug resistance among patients with immunological failure to first-line antiretroviral therapy in south India.

Authors:  Madhavan Vidya; Shanmugam Saravanan; Shanmugasundaram Uma; Nagalingeswaran Kumarasamy; Solomon S Sunil; Rami Kantor; David Katzenstein; Bharat Ramratnam; Kenneth H Mayer; Solomon Suniti; Pachamuthu Balakrishnan
Journal:  Antivir Ther       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.